Carnitine is required for the transport of long chain fatty acids into the mitochondrial matrix, thus allowing their catabolism by ,-oxidation. Carnitine also transports shortened acyl coenzyme A compounds from peroxisomes to mitochondria. Thus carnitine is crucial for mitochondrial energy production, and this is of particular importance in skeletal and heart muscle.' Despite its importance, the regulation of carnitine metabolism is not completely understood. Its endogenous synthesis and urinary excretion have been well established, but no consensus exists concerning the mode of intestinal absorption. Carnitine [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] years, girl:boy 1 2: 1) was studied after eight hours of fasting as reference group. Informed consent was obtained from parents and the study was approved by the hospital institutional review board.
INTESTINAL BIOPSY
All patients (except for the reference group) had upper gastrointestinal endoscopy with a GIF-XQ-10 endoscope (Olympus, Japan). A small intestinal biopsy specimen was taken from the third part of the duodenum, and routinely processed for histological examination. The specimens were graded 1-48 according to the degree of intestinal atrophy.
CARNITINE DETERMINATION
On the day of endoscopy, 5 ml of blood was drawn after eight hours of fasting and the serum was frozen at -70°C until assayed. Serum carnitine was measured by a modified radiometric assay9: total and free carnitine were measured and acyl carnitine was derived from the difference between total and free carnitine. Two ml of ethanol were added to 0 5 ml of serum. After vortexing, the tubes were centrifuged (3000 g for 20 min). The supernatant (0 5 ml) was placed in each one of four tubes (two for total and two for free carnitine). For the determination of total carnitine, 150 >d of ammonia (33%) was added to two tubes and incubated for an hour at 37°C. The contents of the tubes were dried by evaporation. In three coeliac disease patients serum carnitine was measured serially on gluten containing and gluten free diets for at least one year on each of the diets (Table II) . In all three, serum total, free, and acyl carnitine concentrations while on a gluten containing diet were lower in comparison with a gluten free diet.
Free carnitine was converted to '4C acetyl carnitine and measured in a scintillation counter. The carnitine concentration was expressed in .tmol/l. Small intestinal biopsy specimens were histologically normal in the coeliac disease patients on a gluten free diet and in the symptomatic control group. In contrast, intestinal biopsy specimens of the coeliac disease patients not receiving treatment had grade II atrophy in two cases, grade III atrophy in five cases, and total atrophy (grade IV) in five children.
The Figure shows the relation between serum carnitine concentrations and the degree of intestinal atrophy. Patients with grade II-IV of atrophy had significant lower concentrations of total, free, and acyl carnitine in their serum compared with patients with normal intestine (p<0001, p<0001, p<O005, respectively). No correlation was found between the serum carnitine concentration and the degree of intestinal atrophy in active coeliac disease. Patients with coeliac disease who are not receiving treatment have low serum carnitine concentrations. The lower carnitine concentration seems to be secondary to the mucosal injury found in these patients, as a gluten free diet restored not only the injured mucosa, but also returned to normal the serum carnitine concentration.
This study is not longitudinal. The children in group 1 and 2 are not identical, but are demographically comparable. Three patients, however, were followed serially and showed that serum carnitine concentrations are gluten dependent in coeliac disease patients. To strengthen the validity of this conclusion, a group of symptomatic patients without coeliac disease with normal intestinal mucosa was added as a second control group, in addition to age matched normal controls.
Despite the fact that carnitine has not been studied in coeliac disease patients in other geographical areas and dietary carnitine was not studied in our population, it seems that this population does not have nutritional carnitine deficiency. The only diet restricted group in our study, the coeliac disease patients in remission, had normal serum carnitine concentrations, whereas decreased serum carnitine concentrations were found only in patients with symptomatic coeliac disease with intestinal injury.
It thus seems that a histologically normal intestine is a prerequisite for adequate carnitine absorption. Regardless of whether the mechanism of absorption is active or passive,45 the decrease in absorptive surface area, such as occurs in coeliac disease patients, predisposes these patients to carnitine deficiency. Furthermore, carnitine deficiency secondary to poor dietary intake or abnormal intestinal absorption suggests that exogenous carnitine is important in maintaining body carnitine equilibrium.
Carnitine plays a major part in cellular energy production. The insufficiency of long chain fatty acid assimilation in carnitine deficiency may produce lack of energy, weakness, difficulties in gaining weight, and muscular hypotonia. All these features are commonly found in coeliac GCD=gluten containing diet; GFD gluten free diet.
Relation between total (0), In conclusion, coeliac disease should be added to the increasing list of causes of secondary carnitine deficiency. Some of the clinical manifestations in the coeliac disease patient may be a result of carnitine deficiency. Carnitine supplementation for alleviation of some of the symptoms is a subject for further investigation.
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